Vaccitech to join Brookfield’s Harwell Campus
Sep 7, 2021

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced it has signed a lease for 31,000 sq. ft within the Zeus development at Harwell Science and Innovation Campus. The Company plans to relocate its headquarters from Oxford in Spring 2022.

Vaccitech is scaling up operations, taking half of the newly constructed Zeus building. Vaccitech’s fit-out will include state-of-the-art wet laboratory and offices, in a move which will boost UK innovation, research and development in this emerging sector.

In 2020, Brookfield Asset Management secured a 50 percent share in the Campus, investing in Harwell’s five million sq. ft real estate masterplan; A pipeline of purpose built, flexible real estate products, which includes the construction of tailored labs, advanced manufacturing, and grade A office space, to provide opportunities for companies like Vaccitech to scale at pace and grow sustainability.

One and a half million sq. ft will be developed by the mid-2020s to keep pace with occupier demand, half of which will be designated for specialist life science organisations as the campus continues to expand its roster of national and international companies across its multiple clusters including Health, Space, Energy and Quantum. 

The new Zeus building, forms part of the current 180,000 sq. ft development phase and sits alongside Quad Two a 40,000 sq.ft development of grade A offices and BEP0 which will provide 65,000 sq. ft of flexible R&D, lab, office and production space.

Stuart Grant, Chief Executive of Harwell Campus said: “I’m delighted that Vaccitech has chosen the Campus as its base to grow the business and to develop future vaccine manufacturing capability.

“We have an in-depth understanding of the needs of our diverse customer base, which allows us to provide the right environment and tailored space to retain talent and expertise, attract investment into the UK life sciences sector and help the government cement the UK’s position as a global science superpower.”

Vaccitech’s Chief Operating Officer, Chris Ellis, said, “Vaccitech has a broad pipeline of programmes in clinical trials and manufacturing for a biotechnology company of its size. This reflects the ambition, passion and drive that is felt right across the company and its investors as we strive to bring new immunotherapeutics and vaccines to the world. The need for new space designed primarily for state-of-the-art wet laboratory and offices, to house our growing team was our first priority, and staying within the Oxfordshire infrastructure, drove our decision to relocate to the Zeus building at Harwell Campus.”

Vaccitech is the latest company to join Harwell’s Health Cluster which is already home to; the Rosalind Franklin Institute where interdisciplinary research speeds up drug design and pushes forward our understanding of human health and disease; Advanced diagnostic organisations like Oxford Nanopore, whose sequencing technology has been used to track the spread of the virus in more than 85 countries; And the Vaccines Manufacturing and Innovation Centre which, when fully operational will further boost the UK’s global vaccine manufacturing capability. 

The health cluster has trebled in size over the last five years, creating more than 700 new jobs and in June this year, the government committed a further four million pounds of funding, to improve Europe’s largest collection of open access scientific facilities at Harwell, keeping Diamond Light Source and ISIS at the cutting edge of what is scientifically possible.



Notes to editors:

*Savills report:

Harwell Science and Innovation Campus

With a heritage of 75 years at the forefront of UK innovation and discovery, Harwell Campus continues to drive scientific advancements to the benefit of the UK economy and to improve the human condition, centered around an open innovation community and culture. The contribution that Harwell makes to the UK is significant - leading in research and achieving commercial success in key global markets, including Life Sciences, Space, Energy, Supercomputing, AI and Big Data. With 6,000 people employed across +200 public, private, and academic organisations, and an estimated GVA of over £1billion, Harwell provides job creation and economic growth that benefits the whole country.

Follow us on twitter @HarwellCampus, or learn more here


Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.


Vaccitech plc Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements related to Vaccitech’s expectations regarding its continued expansion and the use of the space in the Harwell building. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to timing and advancement of the planned clinical trial and other risks identified in Vaccitech’s SEC filings, including its Quarterly Report on Form 10-Q for the second quarter of 2021 and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vaccitech expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.